Angiotensin II receptor antagonists represent a new class of agents that reduce blood pressure without the side effects of ACE inhibitors, with ongoing research into their broader cardiovascular benefits.
No takes yet. Share an insight, caveat, or question.
Supports ARB use in ACEI-intolerant hypertension; leaves open broader CV outcome benefits.
Leary et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: